Patents Issued in August 4, 2020
  • Patent number: 10729775
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: August 4, 2020
    Assignee: NOVARTIS AG
    Inventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura Ellen West, Thomas Zabawa, Junping Zhao
  • Patent number: 10729776
    Abstract: A composition includes a plurality of coacervate micro and/or nanodroplets of oxidized alginate and a methacrylated gelatin.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: August 4, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Eben Alsberg, Oju Jeon, David Wolfson
  • Patent number: 10729777
    Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: August 4, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Bradley T. Lang, Jared M. Cregg, Jerry Silver, Yi-Lan Weng
  • Patent number: 10729778
    Abstract: Prodrugs or a pharmaceutically acceptable salt thereof which comprise a covalent treprostinil carrier conjugate, as well as their pharmaceutical composition, may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 4, 2020
    Assignee: Ascendis Pharma A/S
    Inventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
  • Patent number: 10729779
    Abstract: The present invention provides a composition having an antifungal activity without depending on conventional compositions having anticandidal activity or combinations of such compositions. The composition comprises a complex of lysozyme bonded to chitosan. The composition according to the present invention is applicable to candidiasis of the skin and mucous membranes, in particular, oral candidiasis and vagina candidiasis affecting a large number of patients and can ameliorate the symptoms of these diseases, heal the same and prevent infection of the same. The composition comprises a complex of lysozyme, which has been widely used as a highly safe natural food additive, with a polysaccharide and, therefore, can reassure patients who use the same and ease their burden. The composition according to the present invention comprises a complex of lysozyme, which is a highly safe natural food additive, with a polysaccharide and, therefore, can be safely used by patients without considering any risk.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: August 4, 2020
    Assignees: Wako Filter Technology Co., Ltd., Teikyo University
    Inventors: Hiroki Kageshima, Akira Saito, Yoichi Murakami, Shigeru Abe, Kazumi Hayama, Miki Takahashi, Miho Abe
  • Patent number: 10729780
    Abstract: The present invention provides methods for preparation of stable multivalent pneumococcal polysaccharide-protein conjugate vaccine formulations. Instant stable formulations show optimal percent adsorption for each conjugate wherein, aggregation can be prevented by employing i) Individual or separate adsorption for conjugates that otherwise show lower percent adsorption by combined adsorption ii) Histidine-Succinic acid buffer system along with shift in pH from neutral pH to acidic pH iii) a polysaccharide to protein ratio between 0.5 to about 1.4 iv) a six-bladed Rushton type turbine impeller in formulation vessels.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 4, 2020
    Assignee: Serum Institute of India Private Ltd.
    Inventors: Rajeev Mhalasakant Dhere, Hitesh Kumar Malviya, Swapan Kumar Jana, Sambhaji Shankar Pisal, Asha Dinesh Mallya, Sunil Mahor, Manish Maheshkumar Gautam, Chetan Vilas Joshi, Venkata Vamsi Krishna Malepati, Prashant Shivaji Jadhav
  • Patent number: 10729781
    Abstract: Isolated or recombinant anti-LGR4 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: August 4, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Qingyun Liu, Xing Gong, Kendra Carmon
  • Patent number: 10729782
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 4, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Takeshi Masuda, Hideki Miyazaki, Yuji Kasuya, Yuki Abe, Yusuke Ogitani
  • Patent number: 10729783
    Abstract: The present invention relates to hollow silica nanoparticles as a drug delivery system loading bioactive ingredients. Particularly, the present invention relates to silica nanoparticles comprising multi-layered silica shells with one or more bioactive ingredients encapsulated within and their applications in drug delivery; and processes of preparing the same.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: August 4, 2020
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: Chung-Yuan Mou, Nai-Yuan Kou, Si-Han Wu, Yi-Ping Chen
  • Patent number: 10729784
    Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 4, 2020
    Assignees: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSM, BIONTECH RNA PHARMACEUTICALS GMBH
    Inventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz, Lars Koste
  • Patent number: 10729785
    Abstract: The present invention relates to particles comprising protamine, RNA and at least one endosome destabilizing agent, to methods of their production and to pharmaceutical compositions or kits containing the particles. It further relates to particles comprising protamine and RNA for use in methods of treatment or prevention of diseases and to kits comprising such particles together with at least one endosome destabilizing agent.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: August 4, 2020
    Assignee: BioNTech SE
    Inventor: Steve Pascolo
  • Patent number: 10729786
    Abstract: Nanoparticles gene carriers, particularly nanoparticle gene carriers which exhibit increased rates of diffusion through cystic fibrosis (CF) mucus, as well as methods of making and using thereof, are described herein. The nanoparticle gene carriers are formed from a nucleic acid complexed to one or more biocompatible, polycationic polymers. The nanoparticle gene carriers also contain one or more mucus resistant polymers. In a particular preferred embodiment, the nanoparticle gene carrier is a nanoparticle formed from one or more nucleic acids, PEI, and a mucus-resistant/diffusive graft copolymer composed of a PEI backbone functionalize by one or more PEG side chains. The nanoparticle gene carriers can efficiently diffuse through CF mucus, and can effectively serve as a vehicle to administer one or more nucleic acids to a patient suffering from CF.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: August 4, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jung Soo Suk, Justin Scot Hanes
  • Patent number: 10729787
    Abstract: The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and/or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and/or diseases or disorders that result in conditions in which muscle is adversely affected.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 4, 2020
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Marija Tadin-strapps, Tayeba Khan, Walter Richard Strapps, Laura Sepp-Lorenzino, Vasant R. Jadhav, Duncan Brown
  • Patent number: 10729788
    Abstract: In alternative embodiments, provided are methods for increasing levels of and/or upregulating the expression of ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) to treat, ameliorate, prevent, reverse, decrease the severity or duration of: a neuropathic pain, including an inflammation-induced neuropathic pain, a nerve or CNS inflammation, a, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy (CIPN) (e.g., cisplatin-induced allodynia) a neurodegeneration or neurodegenerative disease or condition, a migraine, and/or a hyperalgesia.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: August 4, 2020
    Assignee: The Regents of the University of California
    Inventors: Yury Miller, Tony L. Yaksh
  • Patent number: 10729789
    Abstract: The present application discloses a recombinant AAV vector comprising a promoter that targets gene expression to myofibroblast-like lineage of cells in the heart. The present application, also discloses the preparation and use of AAV expression cassettes using a modified periostin promoter that successfully drives gene expression in cardiac myofibroblast-like cells. The present invention encompasses compositions and methods useful for treating myocardial infarction. Further comprising compositions and methods for preparing and using AAV vectors for targeting cells and inducing gene expression. The compositions and methods of the invention are useful for efficiently targeting cardiac myofibroblasts following a cardiac injury, disease, or disorder. Further comprising a kit for effecting alleviation of the various diseases or disorders recited herein.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: August 4, 2020
    Assignee: University of Virginia Patent Foundation
    Inventor: Brent A. French
  • Patent number: 10729790
    Abstract: The present disclosure relates to nucleic acid promoter sequences that are able to specifically express genes operatively linked to the promoter in brainstem and spinal motor neuron cells, and to methods for using such promoters to selectively express genes in motor neurons in vitro and in vivo. It is based, at least in part, on the discovery that the nucleic acid of SEQ ID NO: 1 functioned as a motor neuron-specific promoter and was successful in expressing transgenes in motor neuron cells in vivo. The present disclosure also relates to compositions that can increase the activity or expression level of miR-218 and to compositions that can decrease the expression of miR-218 target nucleic acids.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: August 4, 2020
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventor: Neal Dilip Amin
  • Patent number: 10729791
    Abstract: The application relates to methods for determining a parameter such as toxicity and pharmacokinetic behavior for a pharmaceutical compound against a disease or disorder. The test animals being used are non-human animals not suffering from or is not showing symptoms or signs of the disorder and which do not provoke an immune response against said pharmaceutical compound. These animals are obtainable by administration of a peptide comprising an oxidoreductase motif further comprising an NKT peptide epitope or an MHC class II T cell epitope of said pharmaceutical compound, wherein said motif and said epitope are separated by a linker of between 0 and 4 amino acids.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: August 4, 2020
    Assignee: IMCYSE SA
    Inventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier
  • Patent number: 10729792
    Abstract: There is provided herein, a texaphyrin-phospholipid conjugate, wherein the texaphyrin-phospholipid conjugate comprises a texaphyrin, texaphyrin derivative or texaphyrin analog covalently attached to a lipid side chain of a phospholipid.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: August 4, 2020
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Gang Zheng, Joseph Keca
  • Patent number: 10729793
    Abstract: The invention relates to a method of imaging arthritis in a subject, comprising administering to the subject a tracer which comprises a peptide conjugated to a radionuclide, and imaging the subject by 2D nuclear imaging or by 3D detection of single-photon emission events.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: August 4, 2020
    Assignee: GUY'S AND ST. THOMAS' HOSPITAL NHS FOUNDATION TRUST
    Inventor: Toby Garrood
  • Patent number: 10729794
    Abstract: The invention provides a method for the purification of 227 Th from a mixture comprising 227 Th and 223 Ra, said method comprising: i) preparing a first solution comprising a mixture of 227 Th and 223 Ra ions dissolved in a first aqueous buffer; ii) loading said first solution onto a separation material such as a strong cation exchange resin; iii) eluting 227 Th from the separation material, whereby to generate a second solution comprising 227 Th; iv) Optionally rinsing said separation material using a first aqueous washing medium; The invention additionally provides a method for forming a radio pharmaceutical comprising complexing the purified 227 Th, the pharmaceutical product and its use in treatment of disease such as cancer and a kit for generation of such a product.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: August 4, 2020
    Assignee: BAYER AS
    Inventors: Janne Olsen Frenvik, Olav B. Ryan
  • Patent number: 10729795
    Abstract: A method for sterilizing a concentrated composition and a diluent. The diluent is contained in a large container, and the concentrated composition is contained in a small container that is positioned within the large container. The combined containers are placed in at least one sealing layer that is hermetically sealed, and is also preferably placed in a second sealing layer that is also hermetically sealed. The bagged container is then placed in a carton, which preferably has a liner, and the carton is closed. The carton is then irradiation sterilized. The carton is delivered to the clean room. At a first staging area, the carton is opened and the bagged container is removed and brought to a second staging area. At the second staging area, the second sealing layer is removed and the container can be stored in the first sealing layer. The container is brought into the clean environment, where the first sealing layer is removed.
    Type: Grant
    Filed: January 12, 2004
    Date of Patent: August 4, 2020
    Assignee: Veltek Associates, Inc.
    Inventor: Arthur L. Vellutato, Sr.
  • Patent number: 10729796
    Abstract: A disinfecting unit and method of operating the same includes a cabinet having a vertical axis, a first lamp coupled to the cabinet directing light in a generally radial direction relative to the vertical axis, a second lamp coupled to the cabinet directing light in at least a partially axial direction relative to the vertical axis and a nebulizer that dispenses disinfecting fluid therethrough.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: August 4, 2020
    Assignee: E & C Manufacturing, LLC
    Inventor: Stephen J. Paver, Jr.
  • Patent number: 10729797
    Abstract: UV hard-surface disinfection system that is able to disinfect the hard surfaces in a room, while minimizing missed areas due to shadows by providing multiple UV light towers that can be placed in several areas of a room such that shadowed areas are eliminated and that can be transported by a cart that is low to the ground such that the towers may be loaded and unloaded easily by a single operator. The system is able to be controlled remotely, such that during activation of the system, no operator is present, and to automatically cut power to all towers in the event that a person enters the room.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: August 4, 2020
    Assignee: Surfacide, LLC
    Inventors: Waldemar John Lyslo, Mark Howard Schwartz, Stephen Boyd Pettis
  • Patent number: 10729798
    Abstract: This present invention generally relates to a process for manipulating the chemistry of a product using high voltage atmospheric cold plasma (HVACP) in the presence of a working gas, and in particular to a process for inactivating pathogenic microorganisms in a liquid product by adding an acidic component to or adjusting an acidic component of a product in combination with HVACP treatment. A product of this process is also in the scope of this disclosure.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: August 4, 2020
    Assignee: Purdue Research Foundation
    Inventors: Kevin Michael Keener, Nikhil K Mahnot
  • Patent number: 10729799
    Abstract: An aqueous hydrogen peroxide solution comprises a stabilizer chosen from the family of substituted or unsubstituted aminopolycarboxylic acids (APCA) or salts thereof. The solution may be used for disinfecting a packaging.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 4, 2020
    Assignee: Arkema France
    Inventors: Philippe Zydowicz, Pierre Larnicol
  • Patent number: 10729800
    Abstract: [Object] It is possible to efficiently perfume using a relatively small amount of fragrance material while an increase in size of a perfuming device is minimized. [Solution] Provided is a cartridge for a perfuming device, including: a main body part; an air flow channel that is provided in the main body part and has both ends that are open; and a fragrance material held in at least a part of an inner surface of the air flow channel.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: August 4, 2020
    Assignee: Sony Corporation
    Inventors: Shuji Fujita, Yukari Tsunoda, Tsunetoshi Samukawa, Jusuke Shimura
  • Patent number: 10729801
    Abstract: Disclosed herein are apparatuses and methods for generating non-thermal plasma which can form reactive oxygen species (ROS), such as those used to neutralize bacteria and other pathogens in the air and surrounding area. Also disclosed are apparatuses and methods for neutralizing bacteria and other pathogens using ROS generated through the use of non-thermal plasma. Also disclosed are apparatuses and methods for generating ROS. Also disclosed are apparatuses and methods for treating air and nearby surfaces.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: August 4, 2020
    Assignee: PhoenixAIRE, LLC
    Inventor: Terrance Woodbridge
  • Patent number: 10729802
    Abstract: The present technology relates to composites, apparatuses, systems, and methods that are based on a photocurable composite useful for stabilizing, supporting, or otherwise healing an injured limb. The photocurable composite includes a light-curable resin and a filler material, where the light-curable resin includes about 50 vol % to about 99 vol % (based on the volume of the light-curable resin) of an acrylate-functionalized oligomer, wherein the backbone of the oligomer comprises a polyurethane, a polyether, a polyester, or a combination of any two or more thereof; about 1 vol % to about 50 vol % of a radical-reactive diluent; about 0.001 vol % to about 2 vol % of a photoinitiator; and optionally about 0.05 to about 25 vol % of a surface cure protection agent.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: August 4, 2020
    Assignee: REBOOT MEDICAL INC.
    Inventors: Joseph Lomakin, Madalyn Berns, Jeff Maynard
  • Patent number: 10729803
    Abstract: Disposable absorbent articles assembled from a collection of components using an adhesive comprising an amorphous polyolefin composition and a heterophase polyolefin composition comprising amorphous character and crystalline blocks.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: August 4, 2020
    Assignee: The Procter & Gamble Company
    Inventors: William L. Bunnelle, Robert Haines Turner
  • Patent number: 10729804
    Abstract: The present invention relates to the use of nanofibrillar cellulose hydrogel in cell culture and medical applications. The invention relates to a composition comprising nanofibrillar cellulose, cross linkable polymer and at least one bioactive agent. The invention also provides methods for producing the composition and uses thereof. The present invention further relates to the use of said composition for manufacturing of a shaped matrix, the method of preparing said matrix, the matrix and the use of said matrix in various applications.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: August 4, 2020
    Assignee: UPM-KYMMENE CORPORATION
    Inventors: Marjo Yliperttula, Patrick Lauren, Petter Somersalo, Yanru Lou
  • Patent number: 10729805
    Abstract: Described are polymers and methods of forming and using same.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: August 4, 2020
    Assignee: Terumo Corporation
    Inventors: Gregory M. Cruise, Xinping Wu, Gloria Hincapie, Yue Wu
  • Patent number: 10729806
    Abstract: Moisture-curable adhesive compositions, their preparation and use are disclosed herein. The moisture-curable adhesive compositions include one or more reactive polymers, such as reactive silicone polymers, one or more adhesive components, such as a silicone pressure sensitive polymer(s) (PSAs), a cross-linker and a catalyst. Typically, the reactive silicone polymer or polymers are hydroxyl terminated polydimethylsiloxanes (PDMS) having at least two hydroxyl functionalities associated with the polymer(s).
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: August 4, 2020
    Assignee: Coloplast A/S
    Inventors: Bahar Bingol, Kristoffer Hansen
  • Patent number: 10729807
    Abstract: Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: August 4, 2020
    Assignee: University of Utah Research Foundation
    Inventor: Russell J. Stewart
  • Patent number: 10729808
    Abstract: The invention relates to a sternum replacement implant.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: August 4, 2020
    Assignee: I.CERAM
    Inventors: Daniel Setton, Fabrice Fiorenza, François Bertin, Frank Sturtz, Eric Denes, Delphine Donnez
  • Patent number: 10729809
    Abstract: Provided herein is a bone repair composition that is composed of periosteum containing an angiogenic growth factor(s), cancellous bone chips containing viable osteogenic cells, and, optionally, demineralized bone matrix (DBM) chips. Also provided herein are articles of manufacture and methods of use thereof to treat bone defects.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: August 4, 2020
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Thomas E. Uveges, Jin-Qiang Kuang, Alla Danilkovitch, S. Michael Sinclair, Sandra D. Geraghty
  • Patent number: 10729810
    Abstract: The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: August 4, 2020
    Assignees: CAYMAN CHEMICAL COMPANY, INC, MYOMETRICS LLC
    Inventors: Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Gregory William Endres, Fred Lawrence Ciske, Thomas Allen Owen, James Paul O'Malley
  • Patent number: 10729811
    Abstract: Methods for inhibiting stenosis, obstruction and/or calcification of a heart valve following implantation in a vessel having a wall are disclosed. In one aspect the method includes providing a bioprosthetic heart valve mounted on an elastical stent; treating the bioprosthetic heart valve with a tissue fixative; coating the stent and the bioprosthetic valve with a coating composition including one or more therapeutic agents; implanting the bioprosthetic valve into the vessel in a diseased natural valve site; eluting the coating composition from the bioprosthetic valve; and inhibiting stenosis, obstruction and/or calcification of the bioprosthetic heart valve by preventing the attachment of stem cells to the bioprosthetic heart valve, the stem cells circulating external and proximate to the bioprosthetic heart valve by activating nitric oxide production (i) in the circulating stem cells, (ii) in an endothelial cell lining covering the bioprosthetic heart valve tissue, (iii) or both.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: August 4, 2020
    Assignee: CONCIEVALVE, LLC
    Inventor: Nalini M. Rajamannan
  • Patent number: 10729812
    Abstract: Methods of producing and methods of treatment using a nipple areolar complex extracellular matrix. A method for processing tissue comprises harvesting a human nipple areolar complex tissue, treating the tissue with a stabilizing medium, wherein the medium stabilizes the tissue during transport, decellularizing the tissue, and sterilizing the tissue to form a human nipple areolar complex extracellular matrix scaffold (ECMS). A method of treating an individual with a need for a nipple reconstruction comprises forming an ECMS and applying the ECMS to the individual for nipple areolar regeneration.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: August 4, 2020
    Assignee: NovoThelium, LLC
    Inventors: Bianca G. Cerqueira, Lauren E. Cornell
  • Patent number: 10729813
    Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: August 4, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Stephen F. Badylak, Donald Freytes
  • Patent number: 10729814
    Abstract: The present disclosure relates to cartilage repair compositions and methods for modifying the proteoglycan content of the compositions. Specifically, the methods relate to serum free, collagen free neocartilage made from chondrocytes that can be used for implants. Proteoglycans, such as aggrecan and sulfated glycosaminoglycan are used and the content modified using temperature changes.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: August 4, 2020
    Assignee: Isto Technologies, Inc.
    Inventors: Neil Kizer, Nicole M. Bergmann, Gary Gage, Huston Davis Adkisson, Michael Maloney
  • Patent number: 10729815
    Abstract: A combined treatment for nerve injury is provided. Accordingly there is provided a composition comprising a hyaluronic acid, a laminin polypeptide, an antioxidant and an anti-gliotic agent. Also provided are matrices and hydrogels of the composition and methods of using same.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: August 4, 2020
    Assignees: Ramot at Tel-Aviv University Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
    Inventors: Shimon Rochkind, Zvi Nevo
  • Patent number: 10729816
    Abstract: An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 4, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Yunzhi Yang, Stuart B. Goodman, Yaser Shanjani
  • Patent number: 10729817
    Abstract: A medical device, such as a dilatation balloon, including plasticized nylon, and plasticized nylon.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: August 4, 2020
    Assignee: Medtronic Vascular, Inc.
    Inventor: Mingfei Chen
  • Patent number: 10729818
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 4, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Patent number: 10729819
    Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until implantable device is deployed a an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: August 4, 2020
    Assignee: Micell Technologies, Inc.
    Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
  • Patent number: 10729820
    Abstract: Polymeric coatings, their applications, and the methods of their preparation are described. The coatings may be used to confer desirable properties to the consumer and/or medical products. Also described are methods of loading therapeutic agents on the polymeric coatings and the applications of the drug eluting polymeric coatings thus obtained.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: August 4, 2020
    Assignee: Ariste Medical, LLC
    Inventors: Lisa K. Jennings, Jonathan D. McCanless, Xiaoping Chen, Michael Cole
  • Patent number: 10729821
    Abstract: A method for preparing a chitosan/heparinized graphene oxide composite multilayer film on the surface of a medical magnesium alloy comprises the following steps: firstly preparing negatively charged heparinized graphene oxide; then performing surface chemical treatment and self-assembly of 16-phosphonohexadecanoic acid molecules on the medical magnesium alloy; further covalently immobilizing chitosan on the surface of the magnesium alloy, thereby constructing a positively charged material surface; finally, alternately immersing the surface-modified magnesium alloy material in heparinized graphene oxide and a chitosan solution, and then fully adsorbing, and obtaining the chitosan/heparinized graphene oxide composite multilayer film after drying.
    Type: Grant
    Filed: May 27, 2017
    Date of Patent: August 4, 2020
    Assignee: HUAIYIN INSTITUTE OF TECHNOLOGY
    Inventors: Changjiang Pan, Tao Liu, Tao Gong, Lincai Zhang, Wei Ye
  • Patent number: 10729822
    Abstract: Disclosed herein are compositions to use in biofouling-resistant coatings, biofouling-resistant coatings, methods of making biofouling-resistant coatings, biofouling-resistant devices, and methods of making biofouling-resistant devices.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: August 4, 2020
    Assignees: The Regents of the University of California, Hydrophilix, Inc.
    Inventors: Richard B. Kaner, Dayong Chen, Brian T. McVerry, Ethan Rao, Alexandra L. Polasko
  • Patent number: 10729823
    Abstract: Implantable drug delivery devices include a housing defining a reservoir, a first unit within the reservoir, and a second unit within the reservoir. The first unit contains a drug and the second unit contains a functional agent that facilitates release of the drug. Intravesical drug delivery devices include a housing portion containing a drug formulation and a housing portion containing an excipient, and are configured to release the drug according to a first release profile and the excipient according to a second release profile. Methods include inserting any of these devices into a patient and releasing drug from the device.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: August 4, 2020
    Assignee: TARIS Biomedical LLC
    Inventors: Heejin Lee, Karen Daniel, Matthew Sansone
  • Patent number: 10729824
    Abstract: An implantable biocompatible material includes one or more vacuum deposited layers of biocompatible materials deposited upon a biocompatible base material. At least a top most vacuum deposited layer includes a homogeneous molecular pattern of distribution along the surface thereof and comprises a patterned array of geometric physiologically functional features.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: August 4, 2020
    Assignee: Vactronix Scientific, LLC.
    Inventor: Julio C. Palmaz